Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non-Small Cell Lung CancerReportar como inadecuado




Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in Non-Small Cell Lung Cancer - Descarga este documento en PDF. Documentación en PDF para descargar gratis. Disponible también para leer online.

Journal of Translational Medicine

, 6:38

First Online: 22 July 2008Received: 05 February 2008Accepted: 22 July 2008DOI: 10.1186-1479-5876-6-38

Cite this article as: Baratelli, F., Takedatsu, H., Hazra, S. et al. J Transl Med 2008 6: 38. doi:10.1186-1479-5876-6-38

Abstract

BackgroundOur previous studies have demonstrated that transduction of human dendritic cells DC with adenovirus encoding secondary lymphoid chemokine, CCL21, led to secretion of biologically active CCL21 without altering DC phenotype or viability. In addition, intratumoral injections of CCL21-transduced DC into established murine lung tumors resulted in complete regression and protective anti-tumor immunity. These results have provided the rationale to generate a clinical grade adenoviral vector encoding CCL-21 for ex vivo transduction of human DC in order to assess intratumoral administration in late stage human lung cancer.

MethodsIn the current study, human monocyte-derived DC were differentiated by exposure to GM-CSF and IL-4 from cryopreserved mononuclear cells obtained from healthy volunteers. Transduction with clinical grade adenoviral vector encoding CCL21 1167 viral particles per cell resulted in secretion of CCL21 protein.

ResultsCCL21 protein production from transduced DC was detected in supernatants 24–72 hours, 3.5–6.7 ng-4–5 × 10 cells. DC transduced with the clinical grade adenoviral vector were > 88% viable n = 16, conserved their phenotype and maintained integral biological activities including dextran uptake, production of immunostimulatory cytokines-chemokines and antigen presentation. Furthermore, supernatant from CCL21-DC induced the chemotaxis of T2 cells in vitro.

ConclusionViable and biologically active clinical grade CCL21 gene-modified DC can be generated from cryopreserved PBMC.

Electronic supplementary materialThe online version of this article doi:10.1186-1479-5876-6-38 contains supplementary material, which is available to authorized users.

Felicita Baratelli, Hiroko Takedatsu contributed equally to this work.

Download fulltext PDF



Autor:

Fuente: https://link.springer.com/







Documentos relacionados